Zevra therapeutics presents full data set on the cardiovascular safety and pharmacokinetics of sdx, the sole api in kp1077, in healthy volunteers at psych congress 2023

Celebration, fla., sept. 09, 2023 (globe newswire) -- zevra therapeutics, inc. (nasdaqgs: zvra) (zevra, or the company), a rare disease therapeutics company, today announced a poster presentation featuring study data that underscores the cardiovascular safety profile of serdexmethylphenidate (sdx), the sole active pharmaceutical ingredient (api) in kp1077, zevra's investigational candidate for the treatment for idiopathic hypersomnia (ih), at the psych congress 2023 taking place september 6-10, 2023, in nashville, tennessee.
ZVRA Ratings Summary
ZVRA Quant Ranking